QGEN or RMTI or ZYXI
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
QGEN’s FA Score shows that 1 FA rating(s) are green whileRMTI’s FA Score has 0 green FA rating(s), and ZYXI’s FA Score reflects 0 green FA rating(s).
- QGEN’s FA Score: 1 green, 4 red.
- RMTI’s FA Score: 0 green, 5 red.
- ZYXI’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
QGEN’s TA Score shows that 5 TA indicator(s) are bullish while RMTI’s TA Score has 4 bullish TA indicator(s), and ZYXI’s TA Score reflects 5 bullish TA indicator(s).
- QGEN’s TA Score: 5 bullish, 3 bearish.
- RMTI’s TA Score: 4 bullish, 4 bearish.
- ZYXI’s TA Score: 5 bullish, 3 bearish.
Price Growth
QGEN (@Medical Specialties) experienced а +1.02% price change this week, while RMTI (@Pharmaceuticals: Other) price change was -6.09% , and ZYXI (@Medical Distributors) price fluctuated -31.15% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.02%. For the same industry, the average monthly price growth was -1.15%, and the average quarterly price growth was -2.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.21%. For the same industry, the average monthly price growth was +4.04%, and the average quarterly price growth was -6.96%.
The average weekly price growth across all stocks in the @Medical Distributors industry was +1.74%. For the same industry, the average monthly price growth was -1.08%, and the average quarterly price growth was -10.10%.
Reported Earning Dates
QGEN is expected to report earnings on Aug 12, 2025.
RMTI is expected to report earnings on Aug 18, 2025.
ZYXI is expected to report earnings on Jul 24, 2025.
Industries' Descriptions
@Medical Specialties (+1.02% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+5.21% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Distributors (+1.74% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| QGEN | RMTI | ZYXI | |
| Capitalization | 9.52B | 49.9M | 398M |
| EBITDA | 689M | -4.69M | 17.9M |
| Gain YTD | -1.062 | -47.059 | -79.026 |
| P/E Ratio | 27.85 | N/A | 46.30 |
| Revenue | 1.97B | 83.6M | 184M |
| Total Cash | 1.06B | 10.9M | 44.6M |
| Total Debt | 1.53B | 13.4M | 76.2M |
QGEN | RMTI | ZYXI | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 22 | 5 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 44 Fair valued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 77 | 100 | 100 | |
SMR RATING 1..100 | 87 | 91 | 78 | |
PRICE GROWTH RATING 1..100 | 48 | 91 | 95 | |
P/E GROWTH RATING 1..100 | 3 | 100 | 91 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMTI's Valuation (44) in the Medical Specialties industry is somewhat better than the same rating for QGEN (85) and is somewhat better than the same rating for ZYXI (94). This means that RMTI's stock grew somewhat faster than QGEN’s and somewhat faster than ZYXI’s over the last 12 months.
QGEN's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as RMTI (100) and is in the same range as ZYXI (100). This means that QGEN's stock grew similarly to RMTI’s and similarly to ZYXI’s over the last 12 months.
ZYXI's SMR Rating (78) in the Medical Specialties industry is in the same range as QGEN (87) and is in the same range as RMTI (91). This means that ZYXI's stock grew similarly to QGEN’s and similarly to RMTI’s over the last 12 months.
QGEN's Price Growth Rating (48) in the Medical Specialties industry is somewhat better than the same rating for RMTI (91) and is somewhat better than the same rating for ZYXI (95). This means that QGEN's stock grew somewhat faster than RMTI’s and somewhat faster than ZYXI’s over the last 12 months.
QGEN's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for ZYXI (91) and is significantly better than the same rating for RMTI (100). This means that QGEN's stock grew significantly faster than ZYXI’s and significantly faster than RMTI’s over the last 12 months.
| QGEN | RMTI | ZYXI | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 88% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 51% | 2 days ago 90% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 76% | 2 days ago 81% |
| MACD ODDS (%) | N/A | 2 days ago 86% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 90% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 89% | 2 days ago 80% |
| Advances ODDS (%) | 2 days ago 56% | 8 days ago 84% | 8 days ago 77% |
| Declines ODDS (%) | 11 days ago 50% | 2 days ago 90% | 2 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 90% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 49% | 2 days ago 90% | 2 days ago 84% |
QGEN and
Correlation & Price change
A.I.dvisor indicates that over the last year, QGEN has been loosely correlated with TMO. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if QGEN jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To QGEN | 1D Price Change % | ||
|---|---|---|---|---|
| QGEN | 100% | +0.28% | ||
| TMO - QGEN | 60% Loosely correlated | +0.34% | ||
| A - QGEN | 58% Loosely correlated | +0.13% | ||
| RVTY - QGEN | 57% Loosely correlated | -1.30% | ||
| DHR - QGEN | 56% Loosely correlated | +0.20% | ||
| WAT - QGEN | 52% Loosely correlated | +2.03% | ||
More | ||||
RMTI and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMTI has been loosely correlated with AVDL. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if RMTI jumps, then AVDL could also see price increases.
| Ticker / NAME | Correlation To RMTI | 1D Price Change % | ||
|---|---|---|---|---|
| RMTI | 100% | -1.82% | ||
| AVDL - RMTI | 35% Loosely correlated | +3.37% | ||
| SNDL - RMTI | 29% Poorly correlated | +1.35% | ||
| HROW - RMTI | 28% Poorly correlated | +0.55% | ||
| OPTN - RMTI | 28% Poorly correlated | +0.11% | ||
| ZOMDF - RMTI | 25% Poorly correlated | -1.32% | ||
More | ||||
ZYXI and
Correlation & Price change
A.I.dvisor tells us that ZYXI and HSIC have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZYXI and HSIC's prices will move in lockstep.
| Ticker / NAME | Correlation To ZYXI | 1D Price Change % | ||
|---|---|---|---|---|
| ZYXI | 100% | -24.66% | ||
| HSIC - ZYXI | 25% Poorly correlated | -0.92% | ||
| OMI - ZYXI | 17% Poorly correlated | +0.86% | ||
| EDAP - ZYXI | 11% Poorly correlated | +0.47% | ||
| GEG - ZYXI | 11% Poorly correlated | -0.52% | ||
| AMFPF - ZYXI | 10% Poorly correlated | N/A | ||
More | ||||